Technical Analysis for STX - Shield Therapeutics Plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Historical STX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | -0.87% | |
| Stochastic Sell Signal | Bearish | -0.87% | |
| 180 Bearish Setup | Bearish Swing Setup | -0.87% | |
| Multiple of Ten Bearish | Other | -0.87% | |
| 20 DMA Support | Bullish | -6.25% | |
| Multiple of Ten Bullish | Other | -6.25% | |
| Weak + Overbought | Other | -6.25% | |
| Overbought Stochastic | Strength | -6.25% | |
| Stochastic Reached Overbought | Strength | -5.63% | |
| Multiple of Ten Bullish | Other | -5.63% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| 1.5x Volume Pace | about 4 hours ago | |
| Bearish 180 Entry | about 4 hours ago | |
| Fell Below Previous Day's Low | about 4 hours ago | |
| Down 2% | about 4 hours ago | |
| Down 1% | about 4 hours ago |
Get this analysis on your stocks daily!
Shield Therapeutics Plc Description
Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. The Company's product, Feraccru, is an oral treatment for iron deficiency anemia (IDA) in patients for whom intravenous iron or blood transfusions is needed. It also has a pipeline of over three prescription pharmaceutical assets, including PT20, PT30 and PT40. PT20, which is in Phase II clinical trials, is used as a treatment for hypophosphatemia. PT30, which indicates advanced intravenous (IV) iron formulation, is in pre-clinical stage. Its PT40, which indicates generic IV iron formulation, is in pre-clinical trials. Feraccru, which indicates IDA in chronic kidney disease (CKD) and inflammatory bowel disease (IBD), is in Phase III clinical trials. Its other indications for Feraccru are in Phase II clinical trials.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Health Iron Pharmaceutical Medicine Clinic Pipe Pharmaceuticals Hospital Disease Clinical Trial Blood Rtt Pharmaceutical Industry Phosphate Clinical Research Kidney Disease Chronic Kidney Disease Anemia Design Of Experiments Inflammatory Bowel Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 165.0 |
| 52 Week Low | 39.1 |
| Average Volume | 936,096 |
| 200-Day Moving Average | 103.22 |
| 50-Day Moving Average | 79.27 |
| 20-Day Moving Average | 58.47 |
| 10-Day Moving Average | 58.49 |
| Average True Range | 5.75 |
| ADX | 42.59 |
| +DI | 15.07 |
| -DI | 22.81 |
| Chandelier Exit (Long, 3 ATRs ) | 47.74 |
| Chandelier Exit (Short, 3 ATRs ) | 59.76 |
| Upper Bollinger Band | 65.54 |
| Lower Bollinger Band | 51.40 |
| Percent B (%b) | 0.43 |
| BandWidth | 24.20 |
| MACD Line | -4.68 |
| MACD Signal Line | -6.72 |
| MACD Histogram | 2.0368 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 63.50 | ||||
| Resistance 3 (R3) | 64.00 | 62.50 | 62.50 | ||
| Resistance 2 (R2) | 62.50 | 60.97 | 62.25 | 62.17 | |
| Resistance 1 (R1) | 60.00 | 60.03 | 59.25 | 59.50 | 61.83 |
| Pivot Point | 58.50 | 58.50 | 58.13 | 58.25 | 58.50 |
| Support 1 (S1) | 56.00 | 56.97 | 55.25 | 55.50 | 53.17 |
| Support 2 (S2) | 54.50 | 56.03 | 54.25 | 52.83 | |
| Support 3 (S3) | 52.00 | 54.50 | 52.50 | ||
| Support 4 (S4) | 51.50 |
